How Kite, A Gilead Company, is Building a Global CAR T Franchise out of Los Angeles
57:04
Quality of Life after CAR T-cell Therapy
20:49
Inside Yescarta's Reduced Median Turnaround Time with Kite, a Gilead Company's Christopher McDonald
18:14
2022 Research Briefings: Carl June, University of Pennsylvania Perelman School of Medicine
1:16:44
#128 - POURQUOI L'ÉCONOMIE MONDIALE VA S'EFFONDRER ? PHILIPPE BIHOUIX
1:02:58
Meet the Experts in Drug Development
26:07
L'avenir des drones : des innovations INSENSÉES
6:54
Building a robust supply chain for CAR-T therapies | Kite Pharma
20:09